Skip to main content

7 Result(s)

within E Eigendorff Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Erratum: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

    Correction to: Leukemia (2017) 31, 829–836. doi: 10.1038/leu.2017.9; Published online 11 January 2017 Following the publication of this article, the authors noted that family name of Susanne Sausselele was mis...

    C Schütz, S Inselmann, S Saussele, C T Dietz, M C Müller, E Eigendorff… in Leukemia (2018)

    Download PDF (34 KB) View Article

  2. No Access

    Article

    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

    It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remissio...

    C Schütz, S Inselmann, S Sausslele, C T Dietz, M C Müller, E Eigendorff… in Leukemia (2017)

  3. Article

    Erratum zu: Chronische myeloische Leukämie – State of the Art

    A. Hochhaus, E. Eigendorff, C. Fabisch, T. Ernst in best practice onkologie (2017)

    Download PDF (78 KB) View Article

  4. No Access

    Article

    Chronische myeloische Leukämie — State of the Art

    Prof. Dr. A. Hochhaus, E. Eigendorff, C. Fabisch, T. Ernst in best practice onkologie (2016)

  5. No Access

    Article

    Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

    A minority of chronic myeloid leukemia (CML) patients is capable of successfully discontinuing imatinib. Treatment modalities to increase this proportion are currently unknown. Here, we assessed the role of in...

    A Burchert, S Saussele, E Eigendorff, M C Müller, K Sohlbach, S Inselmann… in Leukemia (2015)

  6. No Access

    Article

    Chronische myeloische Leukämie

    Die Einführung von Tyrosinkinaseinhibitoren (TKI) hat die Prognose von Patienten mit chronischer myeloischer Leukämie (CML) deutlich verbessert. Mit Nilotinib und Dasatinib, Inhibitoren der zweiten Generation,...

    Prof. Dr. A. Hochhaus, P. La Rosée, E. Eigendorff, T. Ernst in Der Internist (2015)

  7. No Access

    Article

    Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

    To study clonal evolution in chronic myeloid leukemia (CML), we searched for BCR-ABL-independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph-positive clones in 29 chronic-phase CML patient...

    M Schmidt, J Rinke, V Schäfer, S Schnittger, A Kohlmann, E Obstfelder, C Kunert… in Leukemia (2014)